The deal includes an upfront payment of $20 million. Stereotaxis could pay up to an additional $25 million if certain regulatory and commercial milestones are met.

The once-daily pill received FDA approval on April 1. However, the agency has requested additional data on multiple potential side effects. 

PFA is still quite safe overall. However, new data out of EHRA 2026 suggest cardiologists have much to learn about minimizing risk during treatment. 

High consumption of these foods could lead to increased levels of intramuscular fat—a known marker of poor muscle health, according to new research published in Radiology. 

The shift comes after a federal court struck down sweeping changes to the pediatric vaccine schedule that went into effect in 2026. The committee of medical experts, which advises on policy at the Centers for Disease Control and Prevention (CDC), will have to focus on a cost-benefit analysis in its future analyses.

SCAI President Srihari S. Naidu, MD, a veteran interventional cardiologist, made a major impact on the group—and cardiology as a whole—over the last 12 months. 

Early data linked the device with short crossing times, reduced fluoro exposure and no device-related adverse events.

According to Heartflow, Cleerly's actions represent “one of the most egregious examples of piracy in the medical technology industry.” Cleerly commented on the lawsuit, defending the value and integrity of its products.